Overview of Эглонил

What is Эглонил? (Quick Overview)

Property	Description
Active Ingredient	Sulpiride (INN)
Form	Capsules, Tablets, Solution for Injection
Pharmacological Class	Atypical Antipsychotic (Substituted Benzamide)
General Purpose	Modulates mood and psychological processes
Origin	Synthetic Compound

The Drug Entity: What Type of Medicine is Эглонил?

Эглонил is fundamentally a synthetic psychotropic drug whose active ingredient is the international non-proprietary name (INN) Sulpiride. This compound is manufactured for its role in modulating specific brain chemistry. It belongs to the neuroleptic or antipsychotic pharmacological class, but is more precisely categorized as a substituted benzamide. Within the wider spectrum of antipsychotics, Sulpiride is often classified as an atypical antipsychotic due to its particular mechanism of action, distinguishing it from older, less-selective agents.

Composition and Form: What is Sulpiride Made of?

The medicinal properties of Эглонил are derived from its single active ingredient, Sulpiride, which is chemically a benzamide derivative obtained from 2-methoxy-5-sulfamoylbenzoic acid. This composition defines its selective pharmacological properties. This substance is commercially prepared for administration in multiple pharmaceutical preparations to ensure flexibility in delivery. These dosage forms include capsules and tablets intended for oral intake, as well as a sterile solution for injection (ampoules) utilized for intramuscular application. Sulpiride's structure is consistent with agents targeting dopamine receptors.

General Purpose: How Does Эглонил Generally Help?

The core function of Sulpiride is based on its ability to modulate the activity of the brain's dopamine system, which regulates mood and perception. It functions as a selective dopamine D2 and D3 receptor antagonist, meaning it specifically blocks these receptors. As a psychotropic agent, this precise mechanism helps to adjust the stability of the central nervous system, which is an approach in managing disturbed psychological processes. Substances in the benzamide class play a role in modulating central nervous system function due to their receptor activity. This indicates that the medicine is primarily used to stabilize disturbances in mood and behavior, offering a supportive role in emotional regulation.

Regulatory References

What side effects are possible with Эглонил?

The official safety profile for the active substance Sulpiride is formally classified based on effects on different physiological systems, as documented in government regulatory sources. These classifications define the documented risk associated with the use of this agent.

Frequency-Classified Adverse Reactions

Adverse reactions classified as common (affecting up to 1 in 10 patients) often involve the endocrine system and nervous system. These include hyperprolactinemia (elevated plasma prolactin levels), sedation or somnolence (drowsiness), and extrapyramidal disorder symptoms such as Parkinsonism and akathesia. Other common effects include weight increase and constipation.

Reactions classified as uncommon include leukopenia (low white blood cell count), orthostatic hypotension, and effects on the reproductive system such as amenorrhea and erectile dysfunction.

Serious Safety Considerations

Regulatory labels document several serious adverse reactions, which are typically classified as rare or having a frequency not known. These include potentially fatal conditions such as Neuroleptic Malignant Syndrome (NMS), which is characterized by rigidity and hyperthermia. The medication is formally associated with the potential for QTc interval prolongation and severe ventricular arrhythmias, including Torsade de pointes and sudden death. Additionally, the development of Venous Thromboembolism (VTE) is listed as a serious concern.

Population-Specific Safety Notes

The official profile specifies that dose reduction is required in individuals with renal impairment, based on creatinine clearance. For older adults, the regulatory text notes an increased possibility of a greater risk of death when the medication is used for psychosis related to dementia. Specific safety notes also exist for newborns exposed during pregnancy, including reports of extrapyramidal symptoms and neonatal withdrawal syndrome.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Key Component	Official Regulatory Statement
Documented Overdose Presentations:	Manifestations typically include a combination of CNS depression (e.g., agitation, confusion, reduced level of consciousness) and extrapyramidal symptoms (EPS), such as muscle stiffness, muscle spasm, trembling, and involuntary movements. Hypotension is also documented.
Physiological Systems Affected:	Effects are documented on the Central Nervous System (CNS), cardiovascular system (specifically QTc interval), and the skeleto-muscular system (EPS).
Population-Specific Overdose Notes:	Neonates exposed during pregnancy should be monitored carefully due to potential effects.
Emergency-Response Statements:	If overdose is suspected, seek immediate medical attention. In the event of signs consistent with Neuroleptic Malignant Syndrome (NMS), prompt discontinuation of Sulpiride and other antipsychotics is required under medical supervision.
When immediate medical help is required:	Tell a doctor or go to a hospital casualty department straight away if overdose is suspected.

Overdose Classifications (High-Level)

Classification Aspect	Official Regulatory Statement
Severity Classification:	The profile indicates potential for life-threatening outcomes, including cardiac arrest and Neuroleptic Malignant Syndrome (NMS), documented as a potentially fatal complication.
Overdose-Context Constraints:	No specific antidote is known. Treatment is largely symptomatic and supportive.

Resulting Overdose Structure

Official Overdose Statements:

Overdose may result in life-threatening outcomes including severe ventricular arrhythmias, QTc interval prolongation leading to Torsade de pointes, and cardiac arrest.
Neuroleptic Malignant Syndrome (NMS) is listed as a serious, potentially fatal complication associated with this medication.
Documented clinical signs of overdose include coma, convulsions, agitation, and severe extrapyramidal symptoms.
Official management instructions specify that patients must be closely monitored for signs of long QT syndrome, often requiring ECG monitoring.

Connection to the overall overdose profile: The official regulatory documents define the overdose profile primarily by its severe potential for cardiovascular toxicity and the onset of Neuroleptic Malignant Syndrome (NMS). Since no specific antidote is known, the profile mandates that emergency medical care be sought immediately upon suspicion of overdose, requiring continuous hospital monitoring and close observation of cardiac and neurological status.

Therapeutic Uses of Эглонил

Main Uses and Therapeutic Benefits of Эглонил

Эглонил (Sulpiride) is applied across domains where additional symptomatic support is needed, primarily focusing on psychiatric and severe behavioral conditions. The medication is commonly used to help with conditions like schizophrenia (addressing both positive and negative symptom clusters), specific forms of depression, and severe behavioral disturbances in children, and may be part of symptomatic management for vertigo (dizziness).

Therapeutic Support

The medication is relevant in contexts marked by increased discomfort or tension, and it is often used when symptoms intensify and supportive relief is needed. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It assists with maintaining functional stability by supporting mood and addressing motivational deficits, which are common in chronic conditions. The medication provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Key Symptom Clusters
Symptom Types: Psychotic symptoms, apathy, tics, and severe behavioral agitation.

Eligibility and Restrictions for Use

The Official Eligibility Profile for Эглонил (Sulpiride)

The official population eligibility for Эглонил, based on international regulatory documents, is strictly defined by age, concurrent conditions, and reproductive status. The primary population permitted to use the medicine are Adults, approved for the management of acute and chronic schizophrenia.

Absolute Exclusions

The medicine is formally contraindicated and must not be used in patients diagnosed with specific conditions, including Phaeochromocytoma, Acute Porphyria, or known prolactin-dependent tumours (such as certain breast cancers). Use is also prohibited in cases of known hypersensitivity to the active substance or excipients.

Restricted and Not Recommended Use

Use is not recommended for children under 14 years of age, as official labeling states that clinical experience is insufficient to permit specific recommendations for this group. Similarly, the medicine is not recommended for women who are pregnant or breastfeeding.

Conditional Eligibility

Eligibility for other populations is conditional. Patients with Renal Impairment are subject to mandatory dose reduction and titration. Furthermore, particular caution is required for individuals with conditions such as a history of epilepsy, risk factors for QT interval prolongation, or Parkinson's disease, as specified in the official warnings and precautions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Sulpiride (the active ingredient in Эглонил) is officially defined by specific prohibitions, mandatory separation rules, and cautions related to pharmacodynamic risks, as documented in regulatory prescribing information.

Interaction Category	Regulatory Statement
Contraindicated Combinations	Co-administration with Levodopa and certain antiparkinsonian dopamine agonists is prohibited due to the risk of reciprocal antagonism of pharmacological effects.
Cardiac Risk Potentiation	Increased risk of QT prolongation and Torsade de Pointes exists with medicines that cause bradycardia (e.g., certain beta-blockers, digitalis) or those that induce hypokalaemia (e.g., certain diuretics, stimulant laxatives).
CNS Depressant Effects	The consumption of alcohol and co-administration with other Central Nervous System (CNS) depressants (e.g., narcotics, benzodiazepines) enhances the sedative effect.
Absorption Interference	Antacids (containing aluminium or magnesium salts) and Sucralfate cause decreased oral absorption of Sulpiride, lowering its plasma concentration.

Interaction Constraints and Specific Notes:

Administration Timing Rule: Sulpiride must be administered at least two hours before antacids or sucralfate to prevent interference with absorption.
Metabolic Status: Sulpiride is largely excreted unchanged; regulatory data indicates that it neither inhibits nor induces major Cytochrome P450 (CYP) enzymes, meaning no clinically significant CYP-mediated interactions are expected with drugs metabolized by these systems.
Population Note: An enhanced effect risk due to drug accumulation from reduced clearance is noted in the official documentation for patients with renal impairment.

Mechanism of Action

Эглонил (Sulpiride) is a substituted benzamide that functions primarily as a dopamine receptor antagonist. Its main biological targets are the D2 and D3 subtypes of dopamine receptors within the central nervous system, particularly in the limbic system.

The interaction type is competitive antagonism. By binding to these G-protein coupled receptors (GPCRs), the drug prevents the endogenous neurotransmitter, dopamine, from binding and initiating the intracellular signaling cascade. This blockade modulates dopaminergic neurotransmission.

At the molecular level, D2 and D3 receptors are coupled to Gi/o proteins. Dopamine binding typically inhibits adenylate cyclase, leading to a decrease in the production of cyclic adenosine monophosphate (cAMP) and a subsequent reduction in protein kinase A (PKA) activity. Эглонил's antagonist action inhibits the Gi/o protein coupling, thereby disinhibiting adenylate cyclase. The downstream cascade results in an increase in intracellular cAMP levels, activating PKA, and altering the phosphorylation state of various target proteins, such as DARPP-32.

This mechanism results in a dose-dependent effect on dopamine pathways. At relatively lower concentrations, the compound preferentially blocks presynaptic dopamine autoreceptors, which are D2 and D3 subtypes. This blockade reduces the negative feedback mechanism controlling dopamine release, leading to an overall functional increase in synaptic dopamine concentration. At higher concentrations, the drug occupies and blocks postsynaptic D2 receptors, resulting in a net decrease in postsynaptic dopaminergic signaling. This system-level modulation of dopaminergic activity occurs in structures including the mesolimbic and mesocortical pathways.

Dosage and Administration Information

Instruction Map: How to use Эглонил — Administration Guidelines

This map details the administration rules for Эглонил (Sulpiride).

Administration Scope

Entity	Instruction
Route of Administration	The primary administration is oral (tablets, capsules, solution). An intramuscular (IM) solution is utilized for initial or acute management phases.
Dosing Schedule	The standard adult starting dose is generally 400 mg to 800 mg daily. The total dose is divided into two administrations per day (twice daily). The maximum daily limit for complex cases is 1200 mg twice daily (2400 mg total).
Timing in Relation to Meals	Oral forms may be taken with or without food.
Preparation Requirements	Tablets should be swallowed whole with water. The scoreline on a tablet is provided only to facilitate breaking for ease of swallowing, not for dividing the unit into equal doses.
Age-Group Administration Rules	Use in the pediatric population under the age of 14 years is not recommended due to insufficient clinical experience. For older adults, the dose must be reduced if there is evidence of impaired kidney function.
Missed-Dose Rules	If a dose is missed, it is generally advised to skip the missed dose and take the next dose at the usual time, if more than half the time to the next dose has passed.
Special Procedural Conditions	Treatment initiation for core conditions requires regular supervision by a specialist.

Instruction Classifications (High-Level)

Classification	Pattern
Administration Method Type	Oral and Intramuscular (IM).
Frequency Pattern	Twice Daily.
Use-Context Constraints	Requires Specialist Supervision for treatment initiation; mandates dose reduction for renal impairment.

Resulting Procedural Structure

Step sequence:

The medicine is primarily administered in an oral form, taken in two divided doses daily.
Dosing is initiated within the established range and is adjusted up to the maximum limit based on standard guidance for specific symptom presentations.
The dosage must be systematically lowered for patients with reduced kidney function.
When treatment is concluded, the dosage must be gradually reduced (tapered) over time rather than stopped suddenly.

Connection to the overall use protocol (2–4 sentences):

The instructions establish a structured protocol that defines the appropriate route of delivery (oral/IM) and the twice-daily dosing schedule. This framework outlines the dose ranges and mandates specific modifications, such as the required dose reduction for individuals with renal impairment, ensuring standardized use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Эглонил (Sulpiride)

This section summarizes the official clinical research and study landscape for Sulpiride (Эглонил), focusing on what has been evaluated, how evidence was gathered, and what remains uncertain, based on authoritative scientific sources.

Evidence for Use in Schizophrenia

Research into the use of Sulpiride for conditions characterized by fluctuating or episodic manifestations, such as schizophrenia, has involved various approaches. Studies explored how symptoms evolved in adult populations, often during periods of increased symptom activity. These studies included Randomized Controlled Trials (RCTs) which compared Sulpiride against both a placebo and other established antipsychotic agents, and also monitored overall global status and daily functioning.

Findings describe patterns observed in the studies over defined, primarily short-term, time intervals (typically 6 to 12 weeks). The available research base often includes older, smaller studies, meaning evidence quality varies across studies. Research examining how Sulpiride compares against newer medications is limited.

Evidence for Use in Depression and Mood-Related Conditions

Sulpiride was studied for its potential role in the study of conditions associated with acute or disruptive episodes, such as Major Depressive Disorder and Dysthymia. The research primarily involved controlled clinical trials, where Sulpiride was compared to placebo or other established antidepressant medications. These studies focused on outcomes related to systemic or functional imbalance, specifically looking at changes in mood and somatic complaints over short-term observation periods.

Studies exploring short-term symptom changes suggest some patterns related to assessing aspects of depressive illness. However, the sample sizes were modest in many of these trials, and the follow-up durations were limited, typically lasting only a few weeks. Long-term outcomes are not fully established.

Consistency, Research Gaps, and Uncertainty

Key research gaps include the need for more robust, large-scale, and long-term studies, especially in pediatric and geriatric populations. The overall body of research for Sulpiride shows differences in design and findings across the conditions studied. The evidence highlights what is known—and what is still uncertain—about the patterns of change observed in the study populations, emphasizing that current research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Эглонил (FAQ)

Q: Can Эглонил be taken at the same time as pain relievers?

A: Regulatory documents indicate that caution is necessary when taking this medicine with other medications, especially those that act as Central Nervous System (CNS) depressants, as this may enhance sedative effects. It is also noted that the medicine must not be taken with Levodopa, an anti-Parkinson's medicine. Official product information notes the importance of disclosing all concurrent medications to a healthcare professional.

Q: Does alcohol interact negatively with Эглонил?

A: According to the official product information, consuming alcohol is noted to enhance the medicine's sedative effects. This interaction is recognized in the regulatory warnings for the drug.

Q: Is there a known 'withdrawal' or stopping effect described when Эглонил is discontinued?

A: Yes, official regulatory documents state that stopping the medicine suddenly may cause specific side effects. These can include nausea, vomiting, insomnia (difficulty sleeping), excessive sweating, and involuntary movement disorders. Therefore, official guidance describes gradually reducing the dosage over time, rather than stopping abruptly.

Q: Is it common for people to experience weight gain while on Эглонил?

A: The official safety profile lists weight increase as a common adverse reaction. This means the effect may be experienced by up to 1 in 10 people using the medicine.

Q: What is the risk of movement disorders associated with Эглонил use?

A: Movement disorders are officially classified as common adverse reactions. These effects are described as extrapyramidal symptoms, which can include Parkinsonism (symptoms similar to Parkinson's disease) and akathesia (a feeling of restlessness and an inability to stay still).

Q: Are there any warnings about combining Эглонил with sedating medications?

A: Regulatory warnings indicate that co-administration with other Central Nervous System (CNS) depressants enhances the sedative effect. These CNS depressants include various medicines such as certain sleeping aids or anxiety medicines.

Q: Does the efficacy of Эглонил change over time?

A: The official research overview notes that the evidence base often consists of older or smaller studies. Consequently, information on long-term outcomes and the possibility of efficacy changes over chronic use is not fully established.

Q: How should a person stop taking Эглонил when treatment is finished?

A: According to the official administration guidance, the dosage must be systematically reduced, or tapered, over a period of time. Regulatory guidance describes that the medicine should be gradually reduced (tapered) rather than stopped suddenly, due to the potential for discontinuation side effects.

Q: Are there any major diet restrictions while taking Эглонил?

A: The oral forms of the medicine may be taken with or without food, as regulatory guidance does not impose specific dietary restrictions. However, the medicine must be taken at least two hours before antacids or sucralfate to prevent interference with its absorption.

Q: Can Эглонил cause changes in sleep patterns?

A: Official documentation lists sedation and somnolence (drowsiness) as common side effects, which affect wakefulness. Additionally, insomnia (difficulty falling or staying asleep) has been reported as a symptom when the medicine is stopped suddenly.

Q: What should be done if a dose of Эглонил is forgotten?

A: Regulatory information advises that if a dose is forgotten, the person should skip the missed dose entirely. The subsequent dose is taken at the usual scheduled time, and regulatory information advises against taking a double dose to compensate for the missed one.

Q: Does taking Эглонил affect driving ability?

A: Due to the common risk of sleepiness, dizziness, or feeling light-headed, official guidance indicates that activities requiring alertness, such as driving or operating machinery, may need to be avoided. These effects may impair attention and motor skills.

Q: Can a person develop a dependence on Эглонил?

A: Regulatory guidance focuses on the need for the medicine to be gradually reduced (tapered) upon discontinuation. This gradual reduction is mandated to prevent the emergence of specific side effects that can occur when the medicine is stopped.

Q: Why is Эглонил sometimes discussed in relation to stomach issues?

A: In some international markets, the medicine has been noted for its efficacy related to the digestive system. Specifically, it has been noted to help in the recovery of the gastric and duodenal mucosa (the lining of the stomach and upper intestine) by increasing blood flow.

Q: What should a patient tell their doctor before starting Эглонил?

A: Official warnings and precautions note that disclosure of specific medical history to a healthcare provider is necessary. This history includes conditions such as epilepsy, heart problems, high blood pressure, Parkinson’s disease, or risk factors for blood clots or QT interval prolongation.

Q: Is it safe to take Эглонил if I have high blood pressure?

A: Regulatory warnings indicate that patients with high blood pressure must exercise particular caution. Consultation with a healthcare provider is noted in official documents before initiating treatment with this medicine.

Q: Are there any common interactions between Эглонил and herbal supplements?

A: Official documentation notes that disclosure of all concurrent medicines, including herbal medicines, is required for the healthcare provider. This is because these supplements can potentially affect how the prescribed drug works.

Q: Does Эглонил have an effect on hormones?

A: Yes, regulatory documents list several hormonal and reproductive system effects. These include hyperprolactinemia (elevated plasma prolactin levels), amenorrhea (loss of menstrual periods), and erectile dysfunction.

Q: What is the difference between the capsule/tablet form and the injection form of Эглонил?

A: The official instructions indicate that the solution for injection, administered intramuscularly (IM), is generally used for initial or acute management phases. The capsule and tablet forms are the primary methods for ongoing, long-term oral treatment.

Q: Can Эглонил be taken on an empty stomach?

A: According to the administration guidelines, the oral forms of the medicine may be taken either with food or on an empty stomach. The timing relative to meals does not generally affect absorption.

Q: Is it possible to have an allergic reaction to Эглонил?

A: Yes, the potential for an allergic or adverse immune response is recognized in the official profile. Known hypersensitivity to the active substance or its excipients is listed as an absolute contraindication for use.

Q: What are the known effects of Эглонил on heart rhythm?

A: The medicine is formally associated with the potential for specific effects on the heart's electrical system. These include QTc interval prolongation (an alteration of heart rhythm) and the risk of severe ventricular arrhythmias, such as Torsade de pointes.

Q: Do researchers know the long-term effects of using Эглонил?

A: The research base highlights that the long-term outcomes from chronic use are not fully established. Official reviews of the evidence indicate that more robust, large-scale, and long-term studies are needed to better understand the effects over extended periods.

Q: Is it necessary to have routine blood tests while taking Эглонил?

A: A doctor may recommend or order routine blood tests during treatment. This is typically done to monitor for potential adverse effects such as a low white blood cell count (leukopenia) or to check for low blood levels of potassium, calcium, and magnesium.

Q: What is the half-life of Эглонил (how long does it stay in the system)?

A: Pharmacokinetic data from authoritative medical sources indicates that the plasma half-life of the active ingredient, sulpiride, is typically described as being between 6 and 8 hours. This is the time it takes for half of the dose to be eliminated from the bloodstream.

Q: Does Эглонил affect appetite?

A: The official safety profile for the medicine lists weight increase as a common adverse reaction. While the mechanism is not explicitly detailed in the patient information, the documentation confirms this common change in weight.

Q: Are there different brand names for the same medicine as Эглонил?

A: Yes, the active ingredient in Эглонил is Sulpiride, which is the international non-proprietary name (INN). This compound is marketed internationally under multiple different brand names, such as Dogmatil and Dolmatil.

Q: Can men experience specific side effects from Эглонил?

A: Yes, documented adverse reactions specific to men include erectile dysfunction (impotence) and gynecomastia (breast enlargement in men).

Q: Can women experience specific side effects from Эглонил?

A: Yes, documented adverse reactions specific to women include amenorrhea (the loss of menstrual periods) and galactorrhea (the abnormal production of breast milk).

How should Эглонил be stored and disposed of?

Storage and Disposal of Eglonyl (Sulpiride)

Eglonyl must be stored under specific environmental conditions to maintain its stability and effectiveness. The medicine must not be stored above 25 C, which supports its labeled 3-year shelf-life.

Required Storage and Safety

The most important safety precaution is that the product must be kept out of the sight and reach of children. The medicine should be stored in its original packaging, typically in PVC/Aluminum foil strips or sealed containers, to maintain integrity.

Disposal of Unused Product

Official regulatory documents state that there are no special precautions for disposal of Eglonyl itself. However, the disposal of any unused or expired medication must be carried out according to local regulations to ensure proper environmental handling.

Эглонил